Biogen’s Alzheimer’s drug lowers toxic protein, but results were mixed
By Julie Steenhuysen CHICAGO, July 14 (Reuters) - The lowest dose of Biogen's anti-tau Alzheimer's drug diranersen, which missed its primary goal in a...
Read the full articleYou might also wanna read
New experimental Alzheimer’s drug shows potential after study shows slower cognitive decline
A study on Biogen's diranersen found it slowed cognitive decline and has promise in treating Alzheimer's disease, researchers found.
Biogen defends anti-tau drug after stock slides on Alzheimer’s readout
Biogen leaders took to an investor call today to defend the phase 2 readout of the company’s anti-tau Alzheimer’s disease candidate, which d
AAIC: Biogen bolsters hopes for Alzheimer's pivotal push as anti-tau oligo slows cognitive decline
Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, backing up the pharm
Experimental Alzheimer’s drug targeting new brain protein shows promise
WASHINGTON — An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’s treatments — by lowerin
An experimental Alzheimer’s drug shows promise targeting a different brain protein, new study shows
By LAURAN NEERGAARD WASHINGTON (AP) — An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’
STAT+: Biogen Alzheimer’s drug slowed decline at rates on par with approved therapies, study shows
An experimental Alzheimer's drug from Biogen, one with a novel approach, slowed decline at comparable rates as approved drugs in a mid-stage
Comments
Sign in to join the conversation.
No comments yet. Be the first.